MID1 and metastatic prostate carcinoma: Several clinical trials targeting the TRIM family such as TRIM18-targeted treatment in patients with hormone-refractory metastatic prostate cancer (ClinicalTrials.gov Identifier: NCT00255606) and TRIM19-targeted treatment in patients with newly diagnosed acute promyelocytic leukemia (ClinicalTrials.gov Identifier: NCT03624270) have been recruited or completed.